Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Commentary|Articles|May 1, 2025
Oncology Experts Highlight the Key Data and Top Abstracts From AUA 2025
Author(s)Chris Ryan
Experts revisit the most intriguing abstracts and data they saw presented at the 2025 American Urological Association Annual Meeting.
Advertisement
Advertisement
Following the
Related to this article
Katie S. Murray, DO, discusses how efficacy, toxicity, patient preferences, and treatment logistics guide BCG-unresponsive NMIBC care.
Vignesh T. Packiam, MD, reviews why improved BCG outcomes support its first-line use, with gemcitabine/docetaxel as a BCG-sparing option.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Advertisement
Advertisement